WEDNESDAY 20th JUNE 2012 COMMENCING 10.30 AM
(UNTIL 4.00 PM APPROX)
AT CARDIFF METROPOLITAN UNIVERSITY, LLANDAFF
CAMPUS, WESTERN AVENUE, CARDIFF CF5 2YB

AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Chairman's report (verbal update)

5. Minutes of previous meeting

6. Appraisal 1
   Belatacept (Nulojix®) for prophylaxis of graft rejection in adults receiving a renal transplant, in combination with corticosteroids and a mycophenolic acid

7. Appraisal 2
   Nevirapine (Viramune®) 400 mg prolonged release tablets in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adults

8. Appraisal 3
   Nevirapine (Viramune®) 50 mg, 100 mg, 400 mg prolonged release tablets in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adolescents and children three years and above and able to swallow tablets

9. Appraisal 4
   Rilpivirine (Edurant®) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment naive adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/ml

10. Appraisal 5
    Rifaximin (Xifaxanta®) for the treatment of travellers diarrhoea that is not associated with any of: fever, bloody diarrhoea, eight or more unformed stools in the previous 24 hours, occult blood or leucocytes in the stool. Rifaximin (Xifaxanta®) may shorten the duration of diarrhoea when this is associated with non-invasive strains of E.coli
11. **AWPAG Update (draft minutes - April 2012)** | 7/AWMSG/0612
12. **CEPP Repeat Prescribing Audit** | 8/AWMSG/0612
13. **Warfarin Monitoring** | 9/AWMSG/0612
14. **Monitored Dosage System Standards** | 10/AWMSG/0612
15. **Date of next meeting - Wednesday, 18th July 2012 in Cardiff**